单胺氧化酶单克隆抗体对大鼠血管源性脑水肿的保护作用

南方医科大学学报 ›› 2004, Vol. 24 ›› Issue (01): 53-56.

单胺氧化酶单克隆抗体对大鼠血管源性脑水肿的保护作用

李强, 陆兵勋, 王心宇

第一军医大学南方医院神经内科, 广东, 广州, 510515

出版日期:2004-01-20 发布日期:2004-01-20
基金资助:
收稿日期:2003-2-27。
作者简介:李强(1968- ),男,1991年毕业于河南医科大学,现为第一军医大学在读硕士研究生,主治医师,电话:020-61641965

Neuroprotective effect of monoamine oxidase monoclonal antibody against vaso genic brain edema in rats

LI Qiang, LU Bing-xun, WANG Xin-yu

第一军医大学南方医院神经内科, 广东, 广州, 510515

Online:2004-01-20 Published:2004-01-20

摘要/Abstract

摘要： 目的观察单胺氧化酶单克隆抗体(MAO mAb)对大鼠血管源性脑水肿(VBE)的治疗作用。方法 75只Wistar大鼠随机分为无脑水肿组、脑水肿未治疗组、脑水肿生理盐水组、脑水肿甘露醇组与脑水肿MAO mAb组。用腹腔注射苯肾上腺素的方法制成VBE模型,然后分别注射生理盐水、甘露醇或MAO mAb到大鼠腹腔,通过远红外线水分分析仪分别测定各组脑灰、白质水分含量百分比。用Evans blue (EB)测定血脑屏障(BBB)的通透性。结果 MAO mAb对减少VBE大鼠脑灰、白质水分含量、降低BBB通透性均有显著效果(P<0.01 ),尤其对白质的脱水作用更显著(P<0.01),而与无脑水肿组想比无显著差异(P>0.05)。甘露醇组也可降低灰质、白质水肿,但对灰、白质无特异性差异,降低BBB通透性差。结论 VBE中BBB的通透性改变与单胺氧化酶活性有关,MAO mAb对VBE尤其对脑白质水肿有选择性治疗作用。

Abstract: Objective To observe the therapeutic effect of monoamine oxidase (MAO) monoclonal antibody (mAb) for vaso-genic brain edema (VBE) in rats.Methods A total of 75 Wistar rats were randomized into non-edema, non-treated edema, sal ine-treated edema, mannitol-treated edema and MAO mAb-treated groups. Rat models of VBE were established by in-traperitoneal injection of phenylephrine in the l atter 4 groups. Brain water content in the gray and white matter was measured r espectively with a moisture analyzer, and the permeability of the blood-brain ba rrier (BBB) determined by Evan’s blue (EB) extravasation method.Results MAO mA b administration significantly reduced the brain water content in the gray and w hite matter as well as the permeability of BBB (P<0.01), Which was especially e ffective for the white matter, producing results comparable with those of the n on-edema group (P>0.05). MAO mAb markedly alleviated brain edema, with better de hydrat-ing effect on the white matter than mannitol (P<0.01), which reduced the water content of the brain gray and white matter undiscriminatingly and showed poor effect on the permeability of BBB.Conclusion The pathogenesis of BBB perme ability changes in VBE is related to the activity of monoamine oxidase, and MAO mAb has selective therapeutic effect on VBE, which is especially obvious on br ain white matter.

中图分类号:

R741.05

李强, 陆兵勋, 王心宇. 单胺氧化酶单克隆抗体对大鼠血管源性脑水肿的保护作用[J]. 南方医科大学学报, 2004, 24(01): 53-56.

LI Qiang, LU Bing-xun, WANG Xin-yu. Neuroprotective effect of monoamine oxidase monoclonal antibody against vaso genic brain edema in rats[J]. Journal of Southern Medical University, 2004, 24(01): 53-56.

参考文献

[1] 陆兵勋,宁群,王心宇.一种新型血管源性脑水肿模型的建立[J].中风与神经疾病杂志,1999,16(5):273-4.Lu BX,Ning Q,Wang XY. Made a new animal model of vasogenic brain edema[J]. J Apople Nerv Dis,1999,16(5):273-4.
[2] Cole DJ,Matsumura JS,Drummond JC,et al. Time-and pressuredependent changes in blood-brain barrier perme-ability after temporary middle cerebral artery occlusion in rats[J]. Acta Neuropathol (Berl),1991,82(4):266-73.
[3] Kondo T,Reaume AG,Huang T,et al. Reduction of CuZn-superoxide dismutase activity exacerbates neuronal cell injury and edema formation after transient focal cerebral ischemia[J]. J Neurosci,1997,17(11):4180-9.
[4] Lee KR,Kawal N,Kin S,et al. Mechanisms of edema formation after intracerebral hemorrhage:effects of thrombin on cerebral blood flow,blood-brain barrier permeability and cerebral in a rat model[J]. J Neurosurg,1997,86 (2):272-8.
[5] Lu BX,Tang XD. A new vasogenic brain edema rmodel and relation to enzymatic barrier[J]. Society Neurosci,1995,21(23):1750-2.
[6] Banks WA,Kastin AJ. Passage of peptides across the blood-brain barrier:pathophysiological perspectives[J]. Life Sci,1996,59(23):1923-43.
[7] Kaufmann AM,Cardoso ER. Aggravation ofvasogenic cerebral edema by multiple-dose mannitol[J]. J Neurosurg,1992,77(4):584-9.
[8] 惠国桢.周幽心,胡锦.外伤性脑水肿脑组织单胺递质变化的实验研究[J].中华神经外科杂志.1994,10(2):74-6.Hui GZ,Zhou YX,Hu J. Experiments for study of changes tissue monoamines in traumatic brain edema[J]. Chin J Neurosurg. 1994,10(2):74-6.
[9] 杨林,王国安,孙璇.大鼠外伤性脑水肿单胺神经递质的改变[J].湖北医科大学学报,2000.21(2):136-8.Yang L,Wang GA,Sun X. The change of catecholamine following traumatic brain injuries in rats[J]. Acta Acad Med Hubei,2000,21(2):136-8.
[10] Ciccone CD. Free-radical toxicity and antioxidant medications in Parkinson’s disease[J]. Phys Ther,1998,78(3):313-9.
[11] Gottowik J,Cesura AM,Malherbe P,et al. Characterization of wildtype and mutant forms of human monoamine oxidase A and B expressed in a mammalian cell line[J]. FEBS Lett,1993,317(1-2):152-6.
[12] Maas JW,Contreras SA,Miller AL,et al. Studies of catecholamine metabolism in schizophrenia/psychosis-Ⅱ[J]. Neuropsychopharmacology,1993,8(2):111-6.
[13] Parkinson Study Group. A controlled trial ofrasagiline in early Parkinson disease:the TEMPO Study[J]. 2002,59(12):1937-43.
[14] Heinonen EH,Savijarvi M,Kotila M,et al. Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer＇sdisease[J]. J Neural Transm Park Dis Dement Sect,1993,5(3):193-202.
[15] 黄华艺,梁熙南,吴祥裼.多巴胺β羟化酶和单胺氧化酶活性与急性脑缺血严重程度间关系的探讨[J].中国危重病急救医学,1996,8(3):142-4.Huang HY,Liang XN,Wu XT. Study of the relationship between dopamine-β- hydroxylase and monoamine oxidase activity and the severity of acute cerebral ischemia[J]. Chin Crit Care Med,1996,8(3):142-4.